CNAT News and Press, Conatus Pharmaceuticals From 04/05/19

Author’s note: I am grateful to Dr. Pascaline Clerc, U.S Campaign Manager, The National Education Program. Introduction 2019, designated as the year of NASH in the biotech industry, was the year to demonstrate the clinical achievements in NASH therapeutics. In the beginning of...

SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct a series of scheduled meetings with investm...

Last week, on March 21, Conatus (NASDAQ: CNAT ) announced that its lead drug candidate, emricasan, had failed to reach its primary endpoint in a Phase 2 clinical trial evaluating the drug's ability to treat NASH fibrosis. On March 22, share price opened at $1.35 (a 53.6% drop from the March 2...

Gainers:  Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im...

The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne...

Conatus Pharmaceuticals (NASDAQ: CNAT )  -55%  after emricasan flunks late-stage NASH study More news on: Conatus Pharmaceuticals Inc., Superconductor Technologies Inc., Motif Bio plc, Stocks on the move, Read more ...

Amarin (NASDAQ: AMRN ) initiated with Buy rating and $27 (44% upside) price target at Stifel citing its allure as an acquisition target. Shares down  1%  premarket. More news on: Amarin Corporation plc, Varian Medical Systems, Inc., Biogen Inc., Healthcare stocks news, Stocks on ...

Nano cap Conatus Pharmaceuticals (NASDAQ: CNAT ) is down  54%  premarket on light volume on the heels of its release of topline results from a Phase 3 clinical trial, ENCORE-NF , evaluating emricasan in patients with nonalcoholic steatohepatitis (NASH) with fibrosis. More news...

SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s ...

Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha...